Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication.
Anna CasajoanaJordi PujolAmador GarciaJordi ElviraNuria VirgiliFrancisco Javier de OcaXavier DuranSonia Fernández-VeledoJoan VendrellNuria VilarrasaPublished in: Obesity surgery (2018)
mRYGB achieves a superior rate of weight loss and T2D remission at month 12. Enhanced GLP-1 secretion 1 month after surgery was a determinant of glucose metabolism improvement. Registration number ( http://www.clinicaltrials.gov ): NCT14104758.
Keyphrases
- gastric bypass
- weight loss
- roux en y gastric bypass
- randomized controlled trial
- bariatric surgery
- disease activity
- obese patients
- ulcerative colitis
- study protocol
- glycemic control
- rheumatoid arthritis
- systemic lupus erythematosus
- type diabetes
- amino acid
- metabolic syndrome
- insulin resistance
- clinical trial
- physical activity
- adipose tissue
- skeletal muscle